GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (STU:YP1B) » Definitions » Ending Cash Position

Immutep (STU:YP1B) Ending Cash Position : €99.80 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Immutep Ending Cash Position?

Immutep's Ending Cash Position for the quarter that ended in Jun. 2024 was €99.80 Mil.

Immutep's quarterly Ending Cash Position declined from Dec. 2023 (€63.67 Mil) to Mar. 2024 (€57.56 Mil) but then increased from Mar. 2024 (€57.56 Mil) to Jun. 2024 (€99.80 Mil).

Immutep's annual Ending Cash Position increased from Jun. 2022 (€53.18 Mil) to Jun. 2023 (€76.45 Mil) and increased from Jun. 2023 (€76.45 Mil) to Jun. 2024 (€99.80 Mil).

Immutep Ending Cash Position Historical Data

The historical data trend for Immutep's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Ending Cash Position Chart

Immutep Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.13 38.45 53.18 76.45 99.80

Immutep Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.33 63.67 57.56 99.80 73.41

Immutep Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Immutep's Ending Cash Position for the fiscal year that ended in Jun. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=76.133+23.67
=99.80

Immutep's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=58.857+40.946
=99.80

Immutep Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Immutep's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (STU:YP1B) » Definitions » Ending Cash Position
Comparable Companies
ASX:BOT ASX:IMU ASX:RAC ASX:CUV ASX:ALA ASX:DXB ASX:LTP ASX:OCC ASX:OPT ASX:EZZ VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
PRRUF:USA IMMP:USA YP1B:Germany IMM:Australia
Address
264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Website
https://www.immutep.com
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Immutep Headlines

No Headlines